HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient.

Abstract
Immunotherapy targeting programmed death-1 or programmed death-ligand 1 has become the standard of care for advanced non-small cell lung cancer (NSCLC). Several recent clinical trials have investigated the efficacy of immune checkpoint inhibitors (ICIs) as neoadjuvant treatment for early NSCLC. However, the safety and feasibility of pulmonary resection after ICIs remain unclear. We herein report a patient in whom cohesion between the left main pulmonary artery and left upper bronchus was found during left upper lobectomy following neoadjuvant ICI combined with chemotherapy. After both central and peripheral sides of the left main pulmonary artery were clamped with the aim of controlling hemorrhage in case of vascular injury, the left main pulmonary artery and left upper bronchus were divided and individually cut with staplers. The thoracoscopic procedure was otherwise uneventful. The patient was discharged from our hospital with no postoperative complications. Thoracic surgeons should anticipate the possible need for management of cohesion between a pulmonary artery and bronchus in patients who have received immune checkpoint inhibitors preoperatively.
AuthorsShinkichi Takamori, Mitsuhiro Takenoyama, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Masafumi Yamaguchi, Ryo Toyozawa, Takashi Seto, Tatsuro Okamoto
JournalThoracic cancer (Thorac Cancer) Vol. 11 Issue 12 Pg. 3605-3608 (12 2020) ISSN: 1759-7714 [Electronic] Singapore
PMID33063937 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Chemical References
  • Immune Checkpoint Inhibitors
Topics
  • Aged
  • Bronchi (pathology)
  • Humans
  • Immune Checkpoint Inhibitors (pharmacology, therapeutic use)
  • Immunotherapy (methods)
  • Lung Neoplasms (drug therapy, physiopathology)
  • Male
  • Pulmonary Artery (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: